Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma

Annals of Surgical Oncology

Volumn 17, Issue 8, 2010, Pages 2247-2254

  Toshimitsu, Hiroaki ^a,b   Yoshimoto, Yasunori ^a,b   Augustine, Christina K ^a,b   Padussis, James C ^a,b   Yoo, Jin S ^a   Selim, M Angelica ^a   Pruitt, Scott K ^a,b   Friedman, Henry S ^a   Ali Osman, Francis ^a   Tyler, Douglas S ^a,b  

^a DUKE UNIVERSITY   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INO 1001; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TEMOZOLOMIDE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DACARBAZINE; INDOLE DERIVATIVE;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MELANOMA; NONHUMAN; RAT; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; EVALUATION STUDY; IN VITRO STUDY; LIMB; NUDE RAT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR CELL LINE;

ALKYLATING AGENTS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DACARBAZINE; DISEASE MODELS, ANIMAL; EXTREMITIES; HUMANS; INDOLES; MELANOMA; POLY(ADP-RIBOSE) POLYMERASES; RATS; RATS, NUDE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; IN VITRO TECHNIQUES;

EID: 77954951941     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-0971-x     Document Type: Article

References (29)

1. Augustine CK, Yoo JS, Potti A, Yoshimoto Y, Zipfel PA, Friedman HS, et al. Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res. 2009;15:502-10.
2. Bignami M, O'Driscoll M, Aquilina G, Karran P. Unmasking a killer: DNA O (6)-methylguanine and the cytotoxicity of methylating agents. Mutat Res. 2000;462:71-82.
3. Tentori L, Portarena I, Graziani G. Potential clinical applications of poly (ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res. 2002;45:73-85.
4. Virag L, Szabo C. The therapeutic potential of poly (ADP-ribose) polymerase inhibitors. Pharmacol Rev. 2002;54:375-429.
5. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res. 2008;14:2900-8.
6. Buschfort C, Muller MR, Seeber S, Rajewsky MF, Thomale J. DNA excision repair profiles of normal and leukemic human lymphocytes: functional analysis at the single-cell level. Cancer Res. 1997;57:651-8.
7. Boulton S, Pemberton LC, Porteous JK, Curtin NJ, Griffin RJ, Golding BT, et al. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly (ADP-ribose) polymerase inhibitors. Br J Cancer. 1995;72:849-56.
8. Haince JF, Rouleau M, Hendzel MJ, Masson JY, Poirier GG. Targeting poly (ADP-ribosyl) ation: a promising approach in cancer therapy. Trends Mol Med. 2005;11:456-63.
9. Tentori L, Leonetti C, Scarsella M, D'Amati G, Vergati M, Portarena I, et al. Systemic administration of GPI 15427, a novel poly (ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res. 2003;9:5370-9.
10. Tentori L, Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res. 2005;52:25-33.
11. Ueno T, Ko SH, Grubbs E, Pruitt SK, Friedman HS, Tyler DS. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am J Surg. 2004;188:532-7.
12. Domoradzki J, Pegg AE, Dolan ME, Maher VM, McCormick JJ. Correlation between O6-methylguanine-DNA-methyltransferase activity and resistance of human cells to the cytotoxic and mutagenic effect of N-methyl-N0-nitro-N- nitrosoguanidine. Carcinogenesis. 1984;5:1641-7.
13. Abdel-Wahab OI, Grubbs E, Viglianti BL, Cheng TY, Ueno T, Ko S, et al. The role of hyperthermia in regional alkylating agent chemotherapy. Clin Cancer Res. 2004;10:5919-29.
14. Ko SH, Ueno T, Yoshimoto Y, Yoo JS, Abdel-Wahab OI, Abdel-Wahab Z, et al. Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity. Clin Cancer Res. 2006;12:289-97.
15. Pepponi R, Marra G, Fuggetta MP, Falcinelli S, Pagani E, Bonmassar E, et al. The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1, 3-bis (2-chloroethyl) 1-nitro-sourea, and cisplatin. J Pharmacol Exp Ther. 2003;304:661-8.
16. Liu L, Markowitz S, Gerson SL. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1, 3-bis (2-chloroethyl) nitrosourea. Cancer Res. 1996;56:5375-9.
17. Cheng CL, Johnson SP, Keir ST, Quinn JA, Ali-Osman F, Szabo C, et al. Poly (ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther. 2005;4:1364-8.
18. Rodon J, Iniesta MD, Papadopoulos K. Development of PARP inhibitors in oncology. Expert Opin Investig Drugs. 2009;18:31-43.
19. Tentori L, Portarena I, Torino F, Scerrati M, Navarra P, Graziani G. Poly (ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G (2)/M cell accumulation induced by temozolomide in malignant glioma cells. Glia. 2002;40:44-54.
20. Farivar AS, Woolley SM, Fraga CH, Thomas R, Salzman AL, Szabo C, et al. Intratracheal poly (ADP) ribose synthetase inhibition ameliorates lung ischemia reperfusion injury. Ann Thorac Surg. 2004;77:1938-43. (Pubitemid 38686562)
21. Alvino E, Marra G, Pagani E, Falcinelli S, Pepponi R, Perrera C, et al. High-frequency microsatellite instability is associated with defective DNA mismatch repair in human melanoma. J Invest Dermatol. 2002;118:79-86.
22. Kroiss MM, Vogt TM, Schlegel J, Landthaler M, Stolz W. Microsatellite instability in malignant melanomas. Acta Derm Venereol. 2001;81:242-5.
23. Palmieri G, Ascierto PA, Cossu A, Colombino M, Casula M, Botti G, et al. Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases. Melanoma Res. 2003;13:167-70.
24. Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, et al. A phase IB of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest. 2009;27:756-63.
25. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, et al. Phase I study of the poly (ADP-Ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res. 2008;14:7917-23.
26. Yasunori Y, Augustine CK, Yoo JS, et al. Optimizing regional infusion treatment strategies for extremity melanoma: predicting tumor response by quantifying the activity of chemotherapy resistance pathways. Mol Cancer Ther. 2007;6:1492-500.
27. Beasley GM, McMahon N, Sanders G, Augustine CK, Selim MA, Peterson B, et al. A Phase I study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer. 2009;115:4766-74.
28. McMahon N, Beasley G, Sanders G, Augustine C, Padussis J, Coleman A, et al. A Phase I study of systemic Sorafenib in combination with isolated limb infusion with melphalan (ILI-M) in patients (pts) with locally advanced in-transit melanoma. ASCO Proceedings, American Society of Clinical Oncology, 2009.
29. Ueno T, Ko SH, Grubbs E, et al. A novel regional strategy for extremity melanoma using modulation of chemotherapy resistance: intra-arterial temozolomide plus systemic O6-benzylgua-nine. Mol Cancer Ther. 2006;5:732-8.